Nasdaq:US$14.78 (-0.38) | HKEX:HK$23.20 (-0.30) | AIM:£2.23 (-0.02)
Search Result
Previous Article   |   Next Article
Scientific Publications | 3 Nov 2021

NANETS 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors